Login to Your Account

ADME-Tox too, please: Evotec paying $68M for Cyprotex

By Cormac Sheridan
Staff Writer

Wednesday, October 26, 2016

DUBLIN – Evotec AG is committing about half of its cash resources to acquire Cyprotex plc in an all-cash deal valued at £55.36 million ($67.5 million), which will add a high-throughput ADME-Tox platform to its preclinical drug discovery research service offerings.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription